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Abstract
Enantioselective syntheses of the alkaloids (−)-aurantioclavine, (+)-amurensinine, (−)-lobeline, and
(−)- and (+)-sedamine are described. The syntheses demonstrate the effectiveness of the Pd-catalyzed
asymmetric oxidation of secondary alcohols in diverse contexts and the ability of this methodology
to set the absolute configuration of multiple stereocenters in a single operation. The utility of an aryne
C–C insertion reaction in accessing complex polycyclic frameworks is also described.
Introduction
Chiral amines are a key functional group in numerous biologically active natural products and
synthetic drugs. The enantioselective synthesis of amines has been extensively investigated
and continues to be a field of intense interest.1 Chiral amines can be accessed from the
corresponding alcohols using several possible approaches. This transformation could, in
principle, be achieved via functional group interconversion of a hydroxyl to an amine
functionality at a stereogenic carbon (Scheme 1a, path A).2 Alternatively, desymmetrization
of a meso-substrate bearing multiple pro-stereogenic centers with alcohol and amine functional
groups could deliver the corresponding enantioenriched product (Scheme 1a, path B).3 In
addition, kinetic resolution of a racemic, diastereomerically pure substrate with stereocenters
bearing hydroxyl and amine functionalities provides a route to chiral amino alcohols (Scheme
1a, path C). Finally, diastereoselective installation of a stereocenter bearing an amine group
can be accomplished from a substrate that already features a hydroxyl-bearing stereocenter
(Scheme 1a, path D). In this article, we present syntheses of natural products bearing chiral
amines or chiral amino alcohols employing each of the above strategies.
We sought to apply the Pd-catalyzed aerobic oxidative kinetic resolution4 (Scheme 1b)
developed in our laboratory toward the synthesis of alkaloids. This transformation enables the
catalytic enantioselective synthesis of chiral alcohols, with benzylic alcohols being particularly
excellent substrates.5 We present here syntheses of the natural products (−)-aurantioclavine
((−)-1), (+)-amurensinine ((+)-2), (−)-lobeline ((−)-3), (−)-sedamine ((−)-4), and (+)-sedamine
(Figure 1) by kinetic resolution or desymmetrization of benzylic alcohols as the key steps.
(−)-Aurantioclavine ((−)-1) is an ergot alkaloid that was first isolated from Penicillium
aurantiovirens.6 The alkaloid possesses a 3,4,5,6-tetrahydro-6-(2-methyl-1-propenyl)azepino
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[5,4,3-cd]indole tricyclic ring system bearing a single stereocenter. We were particularly
interested in aurantioclavine as an intermediate en route to the complex polycyclic alkaloids
of the communesin family7 (Scheme 2). While syntheses of racemic aurantioclavine8 have
been reported in the literature, an asymmetric synthesis of aurantioclavine has, to the best of
our knowledge, not been reported. Our objective was to develop an enantioselective synthesis
of (−)-aurantioclavine ((−)-1) as a means toward an asymmetric synthesis of members of the
communesin family.9
(−)-Amurensinine ((−)-2) belongs to a family of alkaloids, the isopavines (Figure 2), originally
isolated from Papaveraceae plants.10 The isopavines display biological activity relevant to
neurological disorders such as Parkinson's disease, Down's syndrome, Alzheimer's disease,
amyotropic lateral sclerosis and Huntington's chorea. Despite the potential medicinal
applications of the isopavines and their analogues,11 relatively few total syntheses of these
natural products have been reported.12 The majority of these syntheses involve intramolecular
acid-promoted cyclization to form the azabicyclo[3.2.2]nonane core of the isopavines. We
envisioned a catalytic enantioselective approach to rapidly access the isopavine core in a
modular fashion.13
(−)-Lobeline ((−)-3) is a primary alkaloid constituent of Lobelia inflata, a plant commonly
known as “Indian tobacco” because it was previously used by native North Americans as a
tobacco substitute.14, 15 A respiratory stimulant, the plant's crude extracts have been widely
used for the treatment of respiratory illnesses, including asthma, bronchitis, pneumonia, and
whooping cough. (−)-Lobeline mildly mimics the effect of nicotine, is an antagonist of nicotine
acetylcholine receptors, and has thus been applied as a smoking cessation agent.16 (−)-
Lobeline also inhibits the neurochemical and behavioral effects of methamphetamine and is
an inhibitor of dopamine and vesicular monoamine transporter function. (−)-Lobeline is thus
a promising lead in the development of treatments for methamphetamine abuse.17 While it
may be isolated from its natural source and crystallized as a single isomer in salt form, in the
solution state the free base of (−)-lobeline ((−)-3) is known to exist in equilibrium with its
epimer at C(3).18 Due to this known equilibrium, early enantioselective syntheses19 by
Marazano and Lebreton report the synthesis of (−)-lobeline as a mixture with its C(3) epimer.
Our goal was to access the alkaloid 3 in diastereomerically pure form, and we believed that
the application of the Pd-catalyzed enantioselective oxidation would allow efficient access to
(−)-lobeline ((−)-3) from a symmetric meso-intermediate. We also believed that access to either
enantiomer of sedamine (4),20, 21 a piperidine derivative found in various Sedum species,
would be possible through the application of a Pd-catalyzed oxidative kinetic resolution.
Results and Discussion
Retrosynthesis of (−)-aurantioclavine
Our retrosynthetic analysis for (−)-aurantioclavine is depicted in Scheme 3. We believed that
(−)-aurantioclavine ((−)-1) could be accessed from amino alcohol derivative 9 via dehydration
of the tertiary alcohol to form the trisubstituted olefin and subsequent removal of the
sulfonamide protecting groups. Sulfonamide 9 could in turn be derived from amino-diol
derivative 10 via cyclization to form the 3,4,5,6-tetrahydroazepino[5,4,3-cd]indole ring system
of the natural product. Diol 10 could then be derived from enantioenriched diol 12 via amino
alcohol derivative 11. Diol 12 could then be accessed from the known aldehyde 13.
Retrosynthesis of (+)-amurensinine
Our approach to the isopavines, and specifically to amurensinine, is depicted in Scheme 4.
Disconnection of the bridging amine in the natural product reveals azidoester 14, which can
be derived from hydroxyester (−)-15. We envisioned the enantioselective synthesis of this
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benzylic alcohol by Pd-catalyzed oxidative kinetic resolution. Hydroxyester (±)-15 could then
arise from ketoester (±)-16, which we believed could be derived from arylsilyl triflate 17 and
β-ketoester 18 via aryne C–C insertion22 methodology recently developed in our laboratory.
Retrosynthesis of (−)-lobeline
We believed that the late stage Pd-catalyzed oxidative desymmetrization of meso-diol 20, a
natural product known as lobelanidine, could deliver (−)-lobeline ((−)-3, Scheme 5). We also
envisioned that the diastereoselective formation of the desired cis-2,6-disubstituted piperidine
moiety of amino alcohol (−)-3 could be achieved under equilibrating conditions via
intermediate enone 19. Diol 20 could then be derived via disconnection of a C–C bond to arrive
at amino alcohol (±)-21. Enantioselective oxidation of amino alcohol derivative (±)-21 in turn
would allow us to access either (−)-sedamine ((−)-4) or its enantiomer. We believed that amino
alcohol derivative (±)-21 could be readily accessed from aldehyde 22.
Synthesis of (−)-aurantioclavine
Our synthesis of the ergot alkaloid (−)-aurantioclavine commenced with aldehyde 13 (Scheme
6).23 Addition of the dianion derived from isobutylene oxide24 to the aldehyde furnished
racemic diol (±)-12. At this stage, application of a Pd-catalyzed oxidative kinetic resolution
delivered enantioenriched diol, (−)-12 in 96% ee and 37% yield (91% of the theoretical
maximum, selectivity factor25 s = 18.2). Product ketone 23 could be readily recycled by
reduction with lithium aluminum hydride, affording diol (±)-12 in 95% yield.
The enantioenriched diol (−)-12 was then transformed to tricyclic alcohol 9 (Scheme 7). Diol
(−)-12 was treated with hydrazoic acid under Mitsunobu conditions26 to furnish azidoalcohol
24. This transformation was conducted at low temperature to minimize racemization at the
sensitive benzylic stereocenter. Hydrogenation of the azide and protection of the amine as a 2-
nitrobenzenesulfonamide27 delivered sulfonamide 11. Bromination of the indole nucleus was
followed by vinylation of bromoindole 25 under Stille conditions28 to furnish vinyl indole
26. Hydroboration-oxidation29 of the olefin of 26 to amino diol derivative 10 was followed
by formation of the azepine under Mitsunobu conditions to deliver tricyclic alcohol 9 in
excellent yield. We then investigated the dehydration of the tertiary alcohol 9 to (−)-
aurantioclavine (Scheme 8).
Unfortunately, under various reaction conditions30 dehydration of the tertiary alcohol
delivered a mixture of inseparable olefin isomers, with the undesired isomer 28 predominating
in all cases. In an attempt to access the desired trisubstituted olefin isomer, we then turned to
dehydration of intermediate 26 prior to formation of the azepine ring (Scheme 8).
We found that employing phosphorus oxychloride as the dehydrating agent in pyridine as
solvent delivered the desired trisubstituted olefin isomer 29 as the major product. The olefin
isomers 29 and 30 were separable by employing silica gel impregnated with silver nitrate.31
The completion of the synthesis of (−)-aurantioclavine is depicted in Scheme 9. Selective
hydroboration-oxidation of the terminal olefin in vinyl indole 29 delivered the protected amino
alcohol 31, which was then transformed to the tricyclic alcohol 27 under Mitsunobu conditions
in excellent yield. Removal of the o-nitrobenzenesulfonyl protecting group delivered amine
32. Subsequent removal of the tosyl group using tetrabutylammonium fluoride (TBAF)32 then
delivered (−)-aurantioclavine ((−)-1).
Synthesis of (+)-amurensinine
The synthesis of amurensinine began from diazoketone 33, readily available in 5 steps and
95% overall yield from homoveratric acid (Scheme 10). Selective intramolecular C-H insertion
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provided β-ketoester 18 in excellent yield.33 Treatment of β-ketoester 18 with arylsilyl triflate
17, available in 5 steps from sesamol,34 in the presence of cesium fluoride22a afforded
ketoester (±)-16, thereby generating the polycyclic carbon framework of amurensinine in rapid
fashion.
Chemo- and diastereoselective reduction of the ketone of (±)-16 with L-Selectride generated
hydroxyester (±)-15 as a single diastereomer, presumably resulting from equatorial delivery
of hydride to the ketone (Scheme 11).
We then examined the Pd-catalyzed oxidative kinetic resolution of hydroxyester (±)-15. Under
optimized reaction conditions, the racemic alcohol could be resolved to highly enantioenriched
hydroxyester (−)-15 with good selectivity (Scheme 12). Though the overall mass recovery of
(−)-15 and (+)-16 was not ideal, significant quantities of enantioenriched alcohol (−)-15 could
be accessed from this pathway.
We next investigated introduction of the amine required for amurensinine from alcohol
(−)-15. We found that alcohol (−)-15 was unreactive to many common nitrogen-bearing
nucleophiles under Mitsunobu conditions, or it reacted to form a stilbene system by elimination.
However, we were able to install an azide by employing diphenylphosphoryl azide in a
procedure developed specifically for electron-rich benzylic alcohols by Thompson and co-
workers (Scheme 13).35 Reduction of the resulting azide afforded bridged lactam (+)-34.
Lactam reduction and reductive methylation afforded (+)-amurensinine ((+)-2).
While (+)-amurensinine could be accessed by this route, the sequence to (+)-2 from (±)-15 was
complicated by the formation of several side products. Treatment of hydroxyester (−)-15 with
DBU in the absence of diphenylphosphoryl azide produced lactone 35, demonstrating the
sensitivity of the bis-benzylic stereocenter to epimerization (Scheme 14). Of further concern
was the formation of lactam (+)-34 in only 57% ee. This partial racemization required two
stereocenters to be inverted in the azide installation reaction, presumably via an intermediate
such as o-quinonedimethide 36.
Our difficulty in suppressing epimerization at the bis-benzylic stereocenter bearing the ester
in the azide displacement led us to pursue an alternate route to amurensinine via intermediates
with attenuated acidity at the bis-benzylic carbon (Scheme 15). Also, we hoped an alternate
benzylic alcohol substrate would lead to improved mass recovery in the oxidative kinetic
resolution. To this end, reduction of hydroxyester (±)-15 was followed by selective silylation
of the primary alcohol to afford alcohol (±)-37. Oxidative kinetic resolution of this alcohol
proved highly selective (selectivity factor s>47), providing highly enantioenriched alcohol
(−)-37. Interestingly, resolutions that were allowed to proceed to high ee of (−)-37 did not
afford any of the expected ketone (+)-39. Instead, diketone (−)-38 was formed in good yield
and high ee. Monitoring of the reaction demonstrated that the ketone (+)-39 was being
generated, but it slowly underwent further oxidation to the diketone (−)-38. In fact, isolated
samples of ketone 39 were slowly oxidized to the diketone in C6D6. Handling of this ketone
under argon delayed this oxidative decomposition. We hypothesized that ketone (+)-39 was
reacting with molecular oxygen via a radical pathway to afford the diketone (−)-38. This
hypothesis is supported by our observations on non-enantioselective oxidations performed on
alcohol (±)-37. Thus, oxidation of (±)-37 with Dess-Martin periodinane36 cleanly provided
ketone (±)-39, while diketone (±)-38 was obtained when either MnO2 or Pd(OAc)2/O237 was
employed as the oxidant. We therefore screened various radical inhibitors as additives in kinetic
resolutions of alcohol (±)-37. Tetracyanoethylene led to little alcohol oxidation. Neither BHT
nor 2-methyl-2-butene suppressed ketone overoxidation; however, incorporation of even
catalytic quantities of 2-methyl-2-butene enhanced mass recovery and improved selectivity in
the kinetic resolution. While the role of 2-methyl-2-butene is not yet clear, it was included in
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our preparative experiments because of its beneficial effect. Thus, under our optimized
conditions, (±)-37 was resolved with Pd(sparteine)Cl2 as a catalyst in the presence of O2 to
99% ee and was isolated in 47% yield (94% of the theoretical maximum).
Having accessed substantial quantities of highly enantioenriched alcohol (−)-37, we next
proceeded with the installation of the nitrogen required in the natural product. Azide
displacement under Thompson's conditions was followed by desilylation to afford azidoalcohol
(−)-40 (Scheme 16). Gratifyingly, this azide was obtained with clean inversion in 99% ee,
indicating that decreasing the acidity of the bis-benzylic center did indeed minimize SN1
pathways. Oxidation of alcohol (−)-40 in two steps to the corresponding carboxylic acid and
subsequent azide reduction delivered lactam (+)-34. Reduction and methylation as before
afforded (+)-amurensinine ((+)-2) in 99% ee.38
Synthesis of (−)-lobeline and (−)- and (+)-sedamine
Our synthesis commenced from known aldehyde 22.39 Addition of the anion derived from
Horner-Emmons reagent 41 followed by hydrolysis of the resulting methyl enol ether provided
ketone (±)-42 in good overall yield (Scheme 17). DIBAL emerged as the preferred reductant
from a screen of conditions for the subsequent reduction of aryl ketone (±)-42, providing the
amino alcohol derivative (±)-21 with 12:1 diastereoselectivity.40 The diastereomers were
separable by chromatography, and the benzylic alcohol of the major diastereomer (±)-21 was
protected as a TBS ether. Formylation with DMF under anionic conditions furnished aldehyde
43 as a single diastereomer. Aldehyde 43 was then treated with the anion derived from Horner-
Emmons reagent 41. Hydrolysis of the intermediate enol ether afforded ketone 44. As before,
diastereoselective ketone reduction was accomplished with DIBAL, providing a single alcohol
diastereomer. Subsequent desilylation with TBAF, followed by exhaustive reduction of the
carbamate delivered the meso-diol lobelanidine (20). The relative stereochemistry of
lobelanidine was confirmed by x-ray crystallography.
At this stage, we investigated the key desymmetrization of 20 to access (−)-lobeline ((−)-3).
Our previously optimized reaction conditions,41 involving catalytic Pd(sparteine)Cl2 in
chloroform under an oxygen atmosphere, furnished lobeline (3) as a 1:1 mixture of
diastereomers at C(3) in 70% yield and 95% ee (Scheme 18).42 Synthetic alkaloid 3 was found
to be spectroscopically identical to the equilibrated natural isolate and possessed identical
optical rotation. Interestingly, a survey of additives revealed that incubation of Pd(sparteine)
Cl2 with the sodium salt of 6-methoxy-2-naphthol (45) for one hour prior to exposure to
meso-diol 20 had a dramatic impact on the reaction. Inclusion of the phenoxide salt permitted
smooth conversion to amino alcohol (−)-3 with a lowered catalyst loading (10 mol%) and
reaction time (48h) and furnished amino alcohol (−)-3 in enhanced isolated yield (87%) and
ee (99%). Although the role of the phenoxide is presently unclear, one possibility is that the
observed improvement in overall reaction profile may result from the formation of a more
reactive, catalytically competent Pd(sparteine)phenoxide salt.
After implementing a late stage Pd-catalyzed oxidative desymmetrization to access (−)-
lobeline ((−)-3) as a 1:1 mixture of equilibrating diastereomers, we began efforts to control the
epimerization at C(3) in order to access (−)-lobeline as a single diastereomer. The rate of
epimerization of natural (−)-lobeline was found to increase with increasing basicity of the
reaction medium and by protic solvents.43 Furthermore, we found that the hydrochloride salt
3•HCl (cis:trans = 1:1) could be equilibrated to a 3:1 mixture of the cis:trans isomers in i-
PrOH. Prompted by these observations, we developed a dynamic crystallization method
allowing for selective precipitation of the cis-isomer of aminoketone 3 (Scheme 19). Heating
a 1:1 mixture of cis:trans isomers of the hydrochloride of aminoketone 3 in i-PrOH followed
by a slow crystallization permitted a 69% recovery of (−)-lobeline (cis-(−)-3) after liberation
of the free base.
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Having demonstrated a concise total synthesis of isomerically pure (−)-lobeline ((−)-3), we
explored the utility of protected amino alcohol (±)-21 for the synthesis of related Sedum
alkaloids, namely, both enantiomers of sedamine (i.e., (−)- and (+)-4, Scheme 20). Exposure
of protected amino alcohol (±)-21 to our optimized Pd(II)-catalyzed aerobic oxidative kinetic
resolution conditions furnished protected amino alcohol (−)-21 in 94% ee and the oxidation
product, ketone (−)-42, in 81% ee with excellent yield and selectivity.
Direct reduction of amino alcohol derivative (−)-21 with lithium aluminum hydride provided
natural (−)-sedamine ((−)-4). Reiteration of the highly diastereoselective DIBAL reduction of
ketone (−)-42 generated enantiomeric alcohol (+)-21, and further reduction of the carbamate
delivered the non-natural (+)-sedamine ((+)-4).
Conclusion
Herein, we have demonstrated the power of palladium-catalyzed enantioselective aerobic
oxidation toward the synthesis of alkaloid natural products. We have developed an
enantioselective synthesis of the ergot alkaloid (−)-aurantioclavine ((−)-1), a promising
intermediate en route to the communesin family of alkaloids. We have also demonstrated that
the strategic combination of an aryne insertion followed by enantioselective oxidation allows
efficient access to the isopavine alkaloids exemplified by (+)-amurensinine ((+)-2). Finally,
our concise enantioselective synthesis of (−)-lobeline ((−)-3) in diastereomerically pure form,
as well as the synthesis of either enantiomer of sedamine ((−)- or (+)-4), demonstrates the
extraordinarily facile generation of multiple stereogenic centers in a catalytic enantioselective
manner in a single operation.
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Scheme 1a.
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Scheme 1b.
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Figure 1.
Alkaloids with nitrogen-bearing stereocenters.
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Scheme 2.
Krishnan et al. Page 13
J Am Chem Soc. Author manuscript; available in PMC 2008 October 28.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Figure 2.
The isopavine natural products.
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Scheme 3.
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Scheme 4.
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Scheme 6.
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Scheme 8.
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Scheme 9.
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Scheme 14.
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Scheme 17.
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Scheme 18.
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Scheme 19.
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Scheme 20.
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